Cell line · CVCL_1179
DoHH2
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma germinal center B-cell type. 42 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. DoHH2. Cell lines, record CVCL_1179. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1179
On this page
Cell line
As Cellosaurus gives it.
- Name
- DoHH2
- Accession
- CVCL_1179
- RRID
- RRID:CVCL_1179
- Synonyms
- DOHH2, DoHH-2, DOHH-2
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 60Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma germinal center B-cell type (NCIt C36080); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Pleural effusion (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | A TP53 mutation is indicated as being at p.Ala138Pro (c.412G>C) in PubMed=17363600 but has not been confirmed by CCLE and Cosmic-CLP. |
Source Cellosaurus
Papers42
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. | Eur J Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. | Leukemia | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC-driven lymphoma. | EMBO Mol Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 42
See all 42 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | GM12086 | CVCL_1S55 |
Source Cell lines
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-47 | DSMZ | |
| ICLC | HTL99022 | ICLC | |
| IZSLER | BS TCL 228 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1179
GET https://conductscience.org/api/cell-lines/v1/CVCL_1179/papers?page=2